

**2017**[Register for email alerts.](#)[All Categories](#)[Archive](#)

---

**Date** 12/29/17**Title**

Valeant Announces Preliminary Resolution Of Allergan Shareholder Securities Litigation

**Download**[PDF](#)

---

**Date** 12/22/17**Title**

Bausch + Lomb Receives FDA Approval of LUMIFY™ - The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Treatment Of Eye Redness

**Download**[PDF](#)

---

**Date** 12/20/17**Title**

Valeant Completes Sale Of Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals

**Download**[PDF](#)

---

**Date** 12/18/17**Title**

Bausch + Lomb Begins Distribution Of VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% To U.S. Wholesalers

**Download**[PDF](#)

---

**Date** 12/15/17

**Title**

Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes

**Download****PDF****Date**

12/07/17

**Title**

Valeant To Participate At The BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

**Download****PDF****Date**

12/04/17

**Title**

Valeant Announces Pricing Of Private Offering Of Senior Notes

**Download****PDF****Date**

12/04/17

**Title**

Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To \$1,500,000,000 Outstanding Principal Amount

**Download****PDF****Date**

12/04/17

**Title**

Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To \$1,000,000,000 Outstanding Principal Amount

**Download****PDF****Date**

12/04/17

**Title**

Valeant Announces Launch Of Private Offering Of Senior Notes

**Download****PDF****Date**

11/21/17

**Title**

Valeant Announces Closing Of Add-On Secured Notes And Credit Agreement Amendment

**Download**[PDF](#)**Date**

11/21/17

**Title**

Valeant To Participate At The Evercore ISI Biopharma Catalyst/Deep Dive Conference

**Download**[PDF](#)**Date**

11/15/17

**Title**

Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program

**Download**[PDF](#)**Date**

11/14/17

**Title**

Valeant Announces Pricing Of Private Offering Of Add-On Secured Notes

**Download**[PDF](#)**Date**

11/14/17

**Title**

Ortho Dermatologics Announces Aspire Higher Scholarship Honorees

**Download**[PDF](#)**Date**

11/13/17

**Title**

Valeant Announces Launch of Private Offering of Add-On Secured Notes

**Download**[PDF](#)**Date**

11/10/17

**Title**

Valeant Pharmaceuticals Completes Sale of Obagi Medical Products Business to Haitong International Zhongua Finance Acquisition Fund I, L.P.

**Download**

**PDF**

---

**Date**

11/08/17

**Title**

Valeant To Participate At The Stifel 2017 Healthcare Conference

**Download**

**PDF**

---

**Date**

11/07/17

**Title**

Valeant Announces Third-Quarter 2017 Results

**Download**

**PDF**

---

**Date**

11/06/17

**Title**

Valeant Agrees To Sell Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals

**Download**

**PDF**

---

**Date**

11/02/17

**Title**

Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution), 0.024%

**Download**

**PDF**

---

**Date**

11/02/17

**Title**

Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis Treatment

**Download**

**PDF**

---

**Date**

10/31/17

**Title**

Valeant Will Reduce Debt By Additional \$125 Million

**Download****PDF****Date** 10/16/17**Title**

Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes

**Download****PDF****Date** 10/12/17**Title**

Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SiliQ™ (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile

**Download****PDF****Date** 10/04/17**Title**

Solta Medical Receives FDA 510(k) Clearance for Thermage FLX™ System, Newest Generation Skin Smoothing Technology

**Download****PDF****Date** 10/03/17**Title**

Bausch + Lomb Introduces Biotrue® ONEday for Astigmatism Contact Lenses in Europe

**Download****PDF****Date** 10/03/17**Title**

Valeant Will Release Third-Quarter 2017 Financial Results On November 7

**Download****PDF****Date** 10/02/17**Title**

Valeant Announces Pricing Of Private Offering Of Senior Secured Notes

**Download****PDF**

---

**Date** 10/02/17**Title**

Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To \$1,000,000,000 Outstanding Principal Amount

**Download****PDF**

---

**Date** 10/02/17**Title**

Valeant Announces Launch Of Private Offering Of Senior Secured Notes

**Download****PDF**

---

**Date** 09/29/17**Title**

Valeant Pharmaceuticals Completes Sale Of iNova Pharmaceuticals To Pacific Equity Partners And The Carlyle Group

**Download****PDF**

---

**Date** 09/27/17**Title**

Valeant Pharmaceuticals Provides Update On Canadian Regulatory Filing About Future Financing Plans

**Download****PDF**

---

**Date** 09/27/17**Title**

Valeant to Participate at the Deutsche Bank 25th Annual Leveraged Finance Conference

**Download****PDF**

---

**Date** 09/18/17**Title**

Valeant To Participate At The Cantor Fitzgerald Global Healthcare Conference

**Download**

**PDF**

---

**Date** 09/18/17

**Title**

Valeant To Participate At The Cantor Fitzgerald Global Healthcare Conference

**Download**

**PDF**

---

**Date** 09/15/17

**Title**

Valeant Commits \$200,000 to Support Hurricane Relief Efforts

**Download**

**PDF**

---

**Date** 09/06/17

**Title**

Valeant To Participate At The Morgan Stanley Global Healthcare Conference

**Download**

**PDF**

---

**Date** 09/05/17

**Title**

Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118

**Download**

**PDF**

---

**Date** 08/16/17

**Title**

Valeant Receives FDA Confirmation Of Voluntary Action Indicated (VAI) Inspection Classification For Tampa Facility

**Download**

**PDF**

---

**Date** 08/09/17

**Title**

Paulson & Co., Inc. Reiterates Confidence In Valeant Strategy

**Download**

**PDF**

---

**Date** 08/08/17

**Title**

Valeant Announces Second-Quarter 2017 Results

**Download**

[PDF](#)

---

**Date** 08/07/17

**Title**

Valeant Pharmaceuticals Receives Complete Response Letter from the FDA for Latanoprostene Bunod Ophthalmic Solution, 0.024% NDA

**Download**

[PDF](#)

---

**Date** 07/27/17

**Title**

Valeant Announces U.S. Launch of SiliQ™ (brodalumab) Injection

**Download**

[PDF](#)

---

**Date** 07/17/17

**Title**

Valeant Agrees To Sell Obagi Medical Products Business

**Download**

[PDF](#)

---

**Date** 07/13/17

**Title**

Valeant Announces Redemption Of Remaining Approximately \$500 Million Aggregate Principal Amount Of Its Outstanding 6.75% Senior Notes Due 2018

**Download**

[PDF](#)

---

**Date** 07/10/17

**Title**

Valeant Announces Q2 2017 Financial Results Date And Conference Call Details

**Download**

[PDF](#)

---

**Date** 07/10/17

**Title**

Valeant Pays Down \$811 Million of Senior Secured Term Loans

**Download**[PDF](#)

---

**Date**

07/06/17

**Title**

Bausch + Lomb Japan Launches Bausch + Lomb AQUALOX® Contact Lenses

**Download**[PDF](#)

---

**Date**

06/29/17

**Title**

Valeant Pharmaceuticals Completes Sale Of Dendreon To Sanpower Group

**Download**[PDF](#)

---

**Date**

06/28/17

**Title**

Salix Announces Filing Acceptance For Plenvu®\* Next Generation Bowel Cleansing Preparation For Colonoscopies

**Download**[PDF](#)

---

**Date**

06/22/17

**Title**

Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International

**Download**[PDF](#)

---

**Date**

06/19/17

**Title**

Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications

**Download**[PDF](#)

---

**Date**

06/19/17

**Title**

John Paulson Joins Valeant Board Of Directors

**Download**[PDF](#)**Date**

06/08/17

**Title**

Valeant Announces Sale of iNova Pharmaceuticals for \$930 Million

**Download**[PDF](#)**Date**

05/31/17

**Title**

Valeant Pharmaceuticals To Present At Financial Industry Conferences

**Download**[PDF](#)**Date**

05/22/17

**Title**

Bausch + Lomb Introduces renu® Advanced Formula Multi-Purpose Solution

**Download**[PDF](#)**Date**

05/17/17

**Title**

Statement Regarding Xifaxan Intellectual Property Litigation

**Download**[PDF](#)**Date**

05/10/17

**Title**

Valeant Pharmaceuticals To Present At Health Care Conferences

**Download**[PDF](#)**Date**

05/09/17

**Title**

Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range

**Download**

**PDF**

---

**Date** 05/08/17

**Title**

Bausch + Lomb Announces PDUFA Date For New OTC Redness Reliever, Brimonidine Tartrate Ophthalmic Solution, 0.025%

**Download**

**PDF**

---

**Date** 05/05/17

**Title**

Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership

**Download**

**PDF**

---

**Date** 05/03/17

**Title**

Valeant Announces 2017 Annual Meeting Results

**Download**

**PDF**

---

**Date** 05/01/17

**Title**

Valeant Announces Additional Debt Reduction Of Approximately \$220 Million

**Download**

**PDF**

---

**Date** 04/26/17

**Title**

Bausch + Lomb Receives 510(k) Clearance From FDA For Vitesse™, The First And Only Hypersonic, Open-Port Vitrectomy System

**Download**

**PDF**

---

**Date** 04/21/17

**Title**

Valeant's Patient Access And Pricing Committee Announces Pricing For Siliq™ (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis

**Download**

**PDF**

---

**Date** 04/10/17

**Title**

Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call

**Download**

**PDF**

---

**Date** 04/06/17

**Title**

Bausch + Lomb Receives 510(k) Clearance From FDA For Stellaris Elite™ Next-Generation Phacoemulsification Platform

**Download**

**PDF**

---

**Date** 03/30/17

**Title**

Bausch + Lomb ULTRA® for Astigmatism Contact Lenses Introduced

**Download**

**PDF**

---

**Date** 03/21/17

**Title**

Valeant Completes Refinancing Transactions

**Download**

**PDF**

---

**Date** 03/20/17

**Title**

Valeant Announces the Early Results of Tender Offers for Its 6.75% Senior Notes Due 2018

**Download**

**PDF**

---

**Date** 03/20/17

**Title**

Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod

**Download**

**PDF**

---

**Date** 03/15/17

**Title**

Bausch + Lomb Introduces Biotrue® ONEday For Astigmatism Contact Lenses

**Download**

**PDF**

---

**Date** 03/10/17

**Title**

Valeant Receives Lender Consent For Refinancing And Amendment Of Credit Agreement

**Download**

**PDF**

---

**Date** 03/10/17

**Title**

Valeant Announces Upsizing Of Cash Tender Offer For Its 6.75% Senior Notes Due 2018

**Download**

**PDF**

---

**Date** 03/10/17

**Title**

Valeant Announces Pricing And Upsize Of Private Offering Of Senior Secured Notes

**Download**

**PDF**

---

**Date** 03/09/17

**Title**

Valeant Announces Launch Of Private Offering Of Senior Secured Notes

**Download**

**PDF**

---

**Date** 03/07/17

**Title**

Valeant Commences Cash Tender Offer For Up To \$600,000,000 Outstanding Principal Amount Of Its 6.75% Senior Notes Due 2018

**Download**

**PDF**

---

**Date** 03/06/17

**Title**

Valeant Completes Approximately \$1.1 Billion Pay Down Of Senior Secured Term Loans From Divestitures; To Seek Refinancing And Amendment Of Credit Agreement

**Download**

[PDF](#)

---

**Date** 03/03/17

**Title**

Valeant Pharmaceuticals Completes Sale Of CeraVe, AcneFree And AMBI Skincare Brands To L'Oréal

**Download**

[PDF](#)

---

**Date** 03/01/17

**Title**

Valeant Pharmaceuticals Corrects Misleading Report About Salix Investigation

**Download**

[PDF](#)

---

**Date** 02/28/17

**Title**

Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance

**Download**

[PDF](#)

---

**Date** 02/27/17

**Title**

Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity

**Download**

[PDF](#)

---

**Date** 02/27/17

**Title**

Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod

**Download**

[PDF](#)

---

**Date** 02/23/17

**Title**

Obagi Medical Products Announces Collaboration With Suzan Obagi, M.D., And Nextcell Medical To Introduce New Line Of Products

**Download****PDF****Date**

02/21/17

**Title**

Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients

**Download****PDF****Date**

02/16/17

**Title**

Valeant Receives FDA Approval Of SiliQ™ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis

**Download****PDF****Date**

02/13/17

**Title**

Valeant Pharmaceuticals To Participate At Healthcare Conferences

**Download****PDF****Date**

01/30/17

**Title**

Valeant To Hold Conference Call To Present Fourth Quarter And Full Year 2016 Results And Announce 2017 Guidance

**Download****PDF****Date**

01/10/17

**Title**

Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA® For Presbyopia Contact Lenses

**Download****PDF****Date**

01/10/17

**Title**

Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118

**Download****PDF****Date**

01/10/17

**Title**

Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To L'Oreal For \$1.3 Billion

**Download****PDF****Date**

01/09/17

**Title**

Valeant To Sell Dendreon To Sanpower Group For \$819.9 Million In Cash

**Download****PDF****Date**

01/04/17

**Title**

Valeant Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference

**Download****PDF****Date**

01/04/17

**Title**

Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors

**Download****PDF****Investor Inquiries**[ir@bauschhealth.com](mailto:ir@bauschhealth.com)

877-281-6642

514-856-3855 (Canada)

[LEGAL NOTICE](#)[PRIVACY POLICY](#)[EMAIL ALERTS](#)[EMAIL PAGE](#)[RSS FEED](#)**Media inquiries**[Corporate.communications@bauschhealth.com](mailto:Corporate.communications@bauschhealth.com)

908-569-3692

Use of this site signifies your agreement to  
the Legal Notice and Privacy Policy.

©2026 Bausch Health Companies Inc. All rights  
reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY  
PERSONAL INFORMATION

